Macrophages are considered essential mediators in multiple sclerosis (MS) pathogenesis, presumably through myelin phagocytosis and release of inflammatory mediators. Macrophages and microglia express activating Fcg receptors (FcgRI and FcgRIII), which depend on the FcRg chain for surface expression and signaling. In MS lesions, crosslinking of FcgR by immunoglobulins (IgG) directed against myelin may enhance myelin phagocytosis and inflammation. We studied the role of FcgR and anti-myelin antibodies in MOG35-55-induced experimental allergic encephalomyelitis (EAE) in C57BL/6 mice, a model of MS-like disease. Incidence and severity of EAE were similar in FcRg chain 2/2 (FcRg 2/2 ) and wild-type (wt) mice, albeit with delayed onset in FcRg 2/2 mice. This demonstrates that the FcRg chain is not essential for induction of EAE, but that FcRg signaling may contribute to the preclinical phase. The role of FcgR in antibody-mediated demyelination was addressed by injection of anti-myelin antibodies (Z12 mAb) at onset of MOG35-55-induced EAE. Injection of Z12 mAb rapidly reduced survival time in both wt and FcRg 2/2 mice, demonstrating that antibody-mediated exacerbation of EAE is independent of the FcRg chain. Interestingly, Z12-induced exacerbation of inflammation and demyelination persisted longer in wt than FcRg 2/2 mice, suggesting that IgG-FcgR interactions may contribute to a sustained pathologic effect of anti-myelin antibodies in the CNS.
INTRODUCTION
Multiple sclerosis (MS) is a chronic degenerative disease of the central nervous system (CNS), with poorly understood etiology and pathogenesis. In experimental allergic encephalomyelitis (EAE), an animal model that is used to study (auto-) immune inflammation and demyelination in the CNS, both CD4 + T and CD8 + T cells specific for myelin antigens induce lesions highly reminiscent of MS lesions (1) . Importantly, T cells critically depend on macrophages to initiate demyelinating disease (2) . Abundant presence of activated microglia and macrophages containing intracellular myelin debris in active MS lesions suggests that macrophages contribute to the formation of lesions by myelin phagocytosis. Several receptor families are implicated in myelin phagocytosis, including complement receptors and IgG receptors (FcgR) (3) (4) (5) . FcgR enhance phagocytosis of IgG-opsonized particles (6) , thereby forming a bridge between adaptive and innate immunity. In MS lesions, expression of FcgR is enhanced on microglia and macrophages (7) and immunoglobulins are observed in a substantial proportion of active demyelinating MS lesions (8) . At least part of these immunoglobulins specifically bind myelin antigens and can be found within phagocytic macrophages in association with degraded myelin (9) . However, it is unknown to what extent FcgR-mediated myelin phagocytosis contributes to MS lesion formation.
The capacity of FcgR to contribute to myelin phagocytosis was demonstrated in vitro, where myelin-specific antibodies enhanced myelin phagocytosis in absence of active complement (4) . In addition, cultured microglia produced inflammatory chemokines upon FcgR crosslinking, further supporting a pathogenic role for IgG-FcgR interactions in the CNS (10) .
Knockout mice lacking FcgR have improved the understanding of Ig-FcgR interactions in health and disease, including experimental autoimmune diseases (11, 12) . The murine leukocyte FcgR family consists of 3 subclasses (FcgRI, FcgRII, and FcgRIII). The activating FcgRI and FcgRIII are expressed predominantly on myeloid cells and mediate inflammatory effector functions upon crosslinking by IgG-containing immune complexes. For surface expression and signal transduction, both receptors depend on association with the FcRg chain (13) . In FcRg chain-deficient mice (FcRg 2/2 ), functional expression of FcgRI is severely impaired, while expression of FcgRIII is absent (14, 15) . The inhibitory FcgRII is expressed on B cells and myeloid cells (13) . Crosslinking of FcgRII with activating FcgRI or FcgRIII results in downregulation of the activation signal. The balance between activating and inhibitory FcgR is critical for the regulation of antibody-mediated immune responses as demonstrated in several models of infectious and autoimmune diseases (16) (17) (18) (19) .
Recent studies suggest an important role for both activating and inhibitory FcgR in the induction of EAE. Disease in FcRg 2/2 mice was monophasic with low incidence and mild clinical symptoms (20, 21) , while autoimmune prone FcgRII 2/2 mice exhibited more pronounced disease (21) . This led to the conclusion that interactions between anti-myelin antibodies and FcgR are important for the induction of EAE. It remains unclear if IgG-FcgR interactions can contribute to ongoing CNS demyelinating disease. Injection of antibodies directed against the immunodominant myelin oligodendrocyte glycoprotein (MOG) exacerbated EAE in rats and mice (22, 23) , implying that anti-MOG antibodies can contribute to ongoing CNS inflammation and demyelination. Antibodymediated exacerbation of EAE was (partially) independent of complement (22, 24) , suggesting involvement of FcgR.
We explored the role of FcgR in the effector phase of EAE, using the MOG35-55 model that is B cell independent (25). Our hypothesis was that the FcRg chain was not essential for the induction of MOG35-55 EAE, but that FcgR were instrumental in antibody-mediated exacerbation of EAE. Indeed, EAE was reproducibly induced in FcRg 2/2 mice. However, injection of anti-MOG antibodies at onset of EAE rapidly exacerbated clinical EAE in both wt and FcRg 2/2 mice, demonstrating that anti-MOG antibodies can enhance clinical EAE independent of interactions with activating FcgR. Interestingly, sustained CNS inflammation and demyelination in wt but not FcRg 2/2 mice after injection of antibodies suggests that IgG-FcgR interactions may contribute to a sustained pathologic effect of anti-MOG antibodies.
MATERIALS AND METHODS

Animals
C57BL/6 mice were purchased from Harlan Olac (Horst, The Netherlands). FcRg chain knockout mice (FcRg 2/2 ) were generated on the C57BL/6 background in the lab of Dr. T. Saito (26) . All mice were 10 to 20 weeks and weighed 18 to 25 g at the time of EAE induction. Mice were specific pathogen free and had access to chow and water ad libitum. All experiments were performed with approval of the relevant ethical committees.
Antibodies
The monoclonal antibody (mAb) directed against MOG, Z12 mAb, is a mouse IgG2a. The hybridoma and ascites fluid were kindly provided by Dr. Sarah Piddelsden (27) and mAb was grown either at Charing Cross Hospital, London, UK, or at the VUMC, Amsterdam, The Netherlands. Z12 mAb was purified from supernatant or ascitic fluid by affinity chromatography using a protein A Sepharose FF column (Amersham, Roosendaal, The Netherlands). Z12 F(ab#) 2 fragments were produced in the laboratory of Dr. Van 
The Netherlands) emulsified in complete Freund's adjuvant (Difco, Detroit, MI) (1:1, total volume 200 mL) supplemented with 600 mg heat killed Mycobacterium tuberculosis (Difco). After 24 hours, animals were injected intraperitoneally (i.p.) with 400 ng pertussis toxin derived from Bordatella pertussis (Sigma, Zwijndrecht, The Netherlands) in 200 mL saline (NaCl).
Animal were weighed and scored daily for clinical signs of EAE. Clinical disease was graded as follows: 0 = no clinical signs; 1 = limp tail; 2 = unsteady gait, hindlimb weakness; 3 = incomplete hindlimb paralysis; 4 = complete hindlimb paralysis; and 5 = moribund (euthanized) or death. Animals exhibiting signs of a lesser severity than typically observed were scored as 0.5 less than the indicated grade (22) . Mice were killed at day 16 or day 35 using O 2 /CO 2. Serum was collected and stored at 280°C. CNS tissue was collected and stored at 280°C for immunocytochemistry or fixed in formalin before embedding in paraffin wax for histology.
Administration of MOG Z12 Monoclonal Antibody (Z12 mAb)
EAE was induced in C57BL/6 wt or FcRg 2/2 mice and at the onset of clinical signs (limp tail, grade 0.5-1), animals were injected i.p. with 1 mg of Z12 mAb, 1 mg Z12 F(ab#) 2 or an equal volume of saline (NaCl). As the day of onset varied between animals, mice were not all treated on the same day. To limit the variation in day of disease onset (and thus the day of antibody injection) between treatment groups, animals were injected alternately with NaCl, Z12 mAb or Z12 F(ab#) 2 . The first animal to develop EAE was injected with NaCl, the second with Z12 mAb, the third with Z12 F(ab#) 2 , the fourth with NaCl, etc. As a result, the average day of disease onset was comparable for all treatment groups within one strain. As a control, C57BL/6 wt mice were immunized with CFA, MTB, and pertussis toxin in absence of MOG35-55 peptide, and at the time corresponding to onset of EAE in wt mice (day 14), the animals were injected i.p. with 1 mg Z12 mAb.
Histology, Immunohistochemistry, and Immunocytochemistry
Mice were killed 35 days after immunization, and Kluver-Barrera (Luxol fast blue/cresyl violet) staining was performed on formalin-fixed sections of spinal cord and q 2005 American Association of Neuropathologists, Inc.
cerebellum to assess demyelination (28) . Semiquantitative evaluation of demyelination was performed blindly and each section was evaluated three times. Perivascular demyelination, small rims of demyelination centered around blood vessels, and plaque-like demyelination (larger areas of myelin loss that were not obviously associated with blood vessels) were scored independently as absent (2), minor (+), moderate (++), intermediate (+++), or extensive (++++). Total demyelination, the cumulative score for perivascular and plaque-like demyelination, was used for statistical analysis.
Immunocytochemistry on frozen material was used to detect infiltration of macrophages, T cells, B cells, the extent of immune activation (estimated by MHC Class II expression), and expression of FcgRII and FcgRIII. CNS tissue sections (5 mm) were fixed in acetone, followed by incubation with phosphate buffered saline (PBS) containing 0.1% bovine serum albumin (BSA; PAA Laboratories, Linz, Austria) and 5% normal mouse serum to block nonspecific and Fcmediated interactions. After rinsing in PBS, sections were incubated with primary antibody in PBS/0.1% BSA (1 hour, 20°C), followed by another rinse with PBS and incubation with peroxidase (HRP)-conjugated rabbit-anti-rat Ig secondary antibody (DAKO, Glostrup, Denmark) in PBS/0.1% BSA (1 hour, 20°C). After rinsing with PBS, peroxidase activity was visualized using 0.5 mg/mL 3, 3#-diaminobenzidine tetrahydrochloride (DAB) (Sigma) in 0.05 mol/L Tris-HCl buffer (pH 7.6) and 0.03% H 2 O 2 . Immunostaining was assessed quantitatively using the computer program AnalySis (Soft Imaging System GmbH, Münster, Germany), and expressed as the percentage of DAB-positive area in the cerebellum white matter relative to the total cerebellum white matter area. In each group, sections from at least five mice were analyzed, unless stated otherwise.
Statistical Analysis
Differences in day of disease onset, clinical score, and macrophage infiltration between experimental groups were assessed using ANOVA and Student t-test. Disease incidence and survival were analyzed using Pearson's x 2 test. The extent of demyelination in different experimental groups was compared using Mann-Whitney U test. Kaplan-Meier analysis and logrank tests were used to analyze differences in survival of wt and FcRg 2/2 mice after injection of Z12 mAb or saline.
RESULTS
FcgR
2/2 Mice Develop Chronic EAE
EAE was induced in C57BL/6 wt and FcRg 2/2 mice using MOG 35-55 peptide. FcRg 2/2 mice developed chronic disease with similar clinical characteristics as wt mice, albeit with significantly delayed onset (day 15.8 6 3.6 vs day 9.4 6 3.1, respectively; p , 0.05) (Fig. 1a) . No significant differences were observed between FcRg 2/2 and wt mice with respect to disease incidence (13 of 16 and 28 of 31, respectively), maximal clinical score (4.3 6 0.5 and 4.0 6 0.5, respectively) and survival (9 of 13 and 8 of 9, respectively) ( Table 1) .
Histopathology of EAE in wt and FcRg 2/2 mice was evaluated at 35 days after immunization. CNS macrophage infiltration, estimated by the mac-1-positive area in the cerebellar white matter, did not differ between wt and FcRg 2/2 mice ( Fig. 1b ; Table 1 ). Kluver-Barrera staining showed that demyelination was limited and mostly perivascular in both strains (data not shown), with no significant differences between wt and FcRg 2/2 mice ( Table 1) . The experiment was repeated 3 times, yielding similar results.
Exacerbation of EAE after Injection of Z12 mAb Is Independent of the FcRg Chain
The capacity of IgG-FcgR interactions to contribute to ongoing CNS inflammation and demyelination was addressed using a model of antibody-augmented EAE (22, 23) . We first investigated if Z12 mAb was able to exacerbate MOG35-55-induced EAE in C57BL/6 wt mice. A single injection of Z12 mAb at onset of clinical EAE significantly enhanced clinical signs of EAE ( Fig. 2 ; Z12 mAb injection versus NaCl injection, p , 0.05, day 1-4, day 9-12). The diseasemodifying effect of Z12 mAb was dependent on the Fc portion of the antibody, as injection of 1 mg Z12 F(ab#) 2 fragments did not exacerbate clinical EAE (Fig. 2) .
The experiment was repeated using FcRg 2/2 mice and a wt control group. Injection of Z12 mAb dramatically enhanced clinical EAE in both wt and FcRg 2/2 mice. Survival of saline-injected mice after 35 days was 7 of 7 in both strains, whereas survival after injection of Z12 mAb was significantly reduced in both wt and FcRg 2/2 mice (2 of 7 and 3 of 7 respectively; p , 0.05 when compared with saline-injected mice) (Fig. 3 ). C57BL/6 wt mice that died after injection Z12 mAb succumbed at 2.8 6 0.4 days after injection, FcRg Table 1 with Table 2 ). As a result, an increase of clinical scores after injection of Z12 mAb is easier to measure in wt mice than in FcRg 2/2 mice, because in the latter a possible increase in clinical signs may be obscured by high clinical scores of EAE even in absence of antibody. Exacerbation of EAE after Z12 injection in wt mice was observed in 3 independent experiments. This demonstrates that the effect of anti-MOG antibody injection is reproducible, even if there is variability in clinical scores between experiments, a well-known problem of EAE in C57BL/6 mice.
Injection of Z12 mAb in CFA control mice did not cause EAE or reduce survival, confirming that anti-MOG antibodies can exacerbate but not cause clinical EAE and that injection of Z12 in absence of an ongoing CNS inflammatory response is not lethal (Table 2) .
Sustained Effect of Z12 mAb Injection on
Mice that survived injection of Z12 mAb and Z12 F(ab#) 2 -and saline-injected mice were killed 35 days after immunization and the CNS was isolated for histopathologic examination. This was on average 21 days (range, 18-25 days) after injection of Z12 mAb, Z12 F(ab#) 2 or saline. Spinal cords from Z12 mAb-injected mice but not from NaCl-injected mice were in such a poor condition, presumably due to the severity of disease in the CNS, that they could not be extracted. Therefore, we examined cellular infiltration and demyelination in the cerebellum, which is also a good and relevant measure of disease activity in chronic EAE (29, 30) . C57BL/6 wt mice injected with Z12 mAb showed extensive plaque-like and perivascular demyelination, compared to limited perivascular demyelination in saline-injected mice ( Fig. 4A, B ; Table 2 ). The difference between saline and Z12 mAb-injected wt mice was significant (p , 0.05). Unlike previous studies (22, 23, 27) , we carried out this pathologic examination of the brains approximately 3 weeks after injection of Z12 mAb, demonstrating that the effect of antibody administration was not limited to the first days after injection. In wt mice that were injected with Z12 F(ab#) 2 FIGURE 2. Disease modifying effect of Z12 mAb on MOG35-55 EAE in C57BL/6 wt mice. EAE was induced in C57BL/6 wt mice and at first appearance of clinical signs (arrow) animals were injected with 1 mg Z12 mAb (crosses, n = 8), Z12 F(ab#) 2 fragments (open circles, n = 8), or an equal volume of NaCl (filled triangles, n = 9). Injection of Z12 mAb, but not Z12 F(ab#) 2 fragments resulted in exacerbation of clinical EAE. (circles, n = 7) mice, and animals were injected with 1 mg of Z12 mAb (open symbols) or and equal volume of saline (filled symbols) at disease onset (arrow). Z12 mAb significantly reduced survival in both wt and FcRg 2/2 mice within the first 5 days after injection (*, p , 0.05, logrank test). mice did not differ from demyelination in saline-treated FcRg 2/2 or wt mice ( Fig. 4E, F ; Table 2 ). This suggests that IgG-FcgR interactions contribute to the sustained effect of Z12 mAb on demyelination.
Macrophages are thought to actively contribute to demyelination by myelin phagocytosis, therefore we subsequently evaluated macrophage infiltration in the CNS. In wt mice, macrophage infiltration at day 35 was enhanced after injection of Z12 mAb ( Fig. 4C, D ; Table 2 ). Quantitative analysis of MAC-1 staining confirmed enhanced macrophage infiltration in wt mice after injection of Z12 mAb (Fig. 4I) . This difference did not reach statistical significance, probably as a result of the high variation within experimental groups and the low number of mice analyzed in the Z12 mAb-injected group. However, similar results were obtained in 3 independent EAE experiments. Macrophage infiltration in Z12 F(ab#) 2 -treated animals was comparable to saline-treated animals (data not shown).
Although macrophage infiltration at day 35 in salinetreated FcRg 2/2 appeared to be somewhat higher than in saline-treated wt mice, this difference was not significant (Table 2) . A possible trend toward higher macrophage infiltration in FcRg 2/2 mice may reflect the difference in clinical scores between wt and FcRg 2/2 mice in this experiment ( Fig. 4C, G ; Table 2 ). Importantly, injection of Z12 mAb in FcRg 2/2 mice did not enhance macrophage infiltration when compared to injection of saline (Fig. 4G-I) . Again, this suggests that the FcRg chain may contribute to the sustained inflammation and demyelination after injection of anti-MOG antibodies.
DISCUSSION
This study demonstrates that induction and progression of MOG35-55 EAE are independent of the FcRg chain, although delayed onset of EAE in FcRg 2/2 mice suggests a role for FcRg signaling in the preclinical phase of EAE. Furthermore, interactions between IgG and activating FcgR are not essential for anti-MOG antibody-mediated exacerbation of EAE. However, IgG-FcgR interactions may contribute to a sustained effect of anti-MOG antibodies on CNS inflammation and demyelination.
The relevance of B cells and antibodies in EAE is debated, and the interpretation of data is complicated by the variety of models that are used. The role of B cells is best characterized in MOG-induced EAE in C57BL/6 and DBA/1 mice. Consequently, the role of FcgR has been addressed in these models (20, 21) .
In C57BL/6 mice, the origin of the MOG protein is crucial for the role of B cells in EAE. Induction of EAE using recombinant human MOG (rhMOG) is B cell-dependent, whereas immunization protocols using rat derived MOG35-55 peptide or recombinant rat MOG (rrMOG) are independent of B cells (25, 31) . MOG35-55-and rrMOG-induced EAE in B cell-deficient C57BL/6 mice are indistinguishable from EAE in wt mice with regard to disease incidence, onset, severity, and CNS pathology (25) . This is in line with our finding that C57BL/6 FcgR 2/2 mice are susceptible to MOG35-55-induced EAE. Delayed onset of EAE in FcgR 2/2 mice may be related to absence FcRg chain signaling functions that are unrelated to IgG receptors. Observations on the role of B cells and FcgR in EAE in DBA/1 mice support this. B cell-deficient DBA/1 mice develop EAE after immunization with rrMOG, although clinical severity and demyelination are lower than in wt DBA/1 mice (32). Interestingly, the effect of FcRg deficiency is more dramatic: EAE in FcRg 2/2 DBA/1 mice was nearly absent (21) .
The FcRg chain associates with at least six FcRunrelated receptor complexes in leukocytes, including the gdT cell receptor (33) (34) (35) (36) (37) . The role of FcRg chain in these receptor complexes is ill defined and as consequence FcRg 2/2 mice have been considered almost exclusively as mice lacking activating FcgR, thereby possibly ignoring less obvious deficiencies.
Earlier studies reported severely attenuated MOG35-55 EAE in B6129PF2 FcRg 2/2 mice (20, 38). The immunization protocol was similar to ours and mice were of the same H2 4. CNS inflammation and demyelination in antibody-exacerbated EAE in wt and FcgR 2/2 mice. Brains were isolated 35 days after immunization and the cerebellum white matter was analyzed for demyelination using Kluver-Barrera staining (A, B, E, F) and inflammation using mac-1 staining (C, D, G, H). In wt mice, injection of Z12 mAb resulted in enhanced demyelination (B) and inflammation (D) when compared to saline-injected animals (A and C, respectively). In FcRg 2/2 mice, injection of Z12 mAb did not change demyelination (F) or inflammation (H) compared to saline-treated mice (E, G (42) .
The capacity of anti-MOG antibodies to contribute to an ongoing CNS inflammatory and demyelinating response was previously demonstrated in models of antibody augmented EAE (22, 23) . The present study demonstrates that anti-MOG antibody-mediated disease exacerbation is dependent on the Fc part of the injected antibody, but independent of the FcRg chain. This implicates that the pathologic effect of antibodies results from Fc-mediated complement activation. Although the role of complement activation in MOG35-55-induced EAE has been debated (43) (44) (45) , complement activation may be relevant in the context of antibody exacerbated EAE. In rats, the in vivo demyelinating potential of anti-MOG antibodies was correlated to their complement fixing capacity (27) . Z12 mAb has high complement fixing capacity in vitro (27) , possibly explaining the severe effect of Z12 mAb injection on clinical EAE in both wt and FcRg 2/2 mice. Deposition of C9, indicative of full complement activation, was observed in CNS lesions in association with exogenous anti-MOG antibodies, 2 days after injection in animals with EAE (27) . At 6 days after antibody injection, C9 deposition was markedly lower, demonstrating that complement activation after antibody injection is a short-term event (46) . This supports the idea that the rapid effect of antibody injection in both wt and FcRg 2/2 mice is complement-mediated, although redundancy of FcgR and complement in antibody-exacerbated EAE cannot be excluded. Indeed, wt mice succumbed faster to antibody exacerbated EAE than FcRg 2/2 mice, possibly reflecting a delayed response due to absence of FcgRmediated actions. In addition, previous studies demonstrated that complement depletion cannot (24), or not completely (22) , prevent acute exacerbation of EAE by anti-MOG mAb, whereas the present study demonstrates that deletion of the FcgR does not abolish the acute effect of anti-MOG mAb. This supports redundancy of FcgR-and complement-mediated pathways, as previously described in a model of antibodydependent vitiligo (47) .
Although the immediate effect of Z12 mAb on EAE severity was independent of FcgR, interactions between IgG and FcgR may contribute to a sustained effect of anti-MOG antibodies on inflammation and demyelination. On average, 3 weeks after injection of Z12 mAb, wt mice showed enhanced CNS demyelination and inflammation, whereas FcRg 2/2 mice did not. The half-life of IgG2a in serum is 6 to 8 days (48), therefore, enhanced cerebellum pathology after up to at least 25 days after injection is unlikely to result from direct deposition of Z12 mAb. Furthermore, at the time of antibody injection, blood-brain barrier damage in the cerebellum is limited in comparison with the spinal cord (49) . Two mice that were killed 2 days after Z12 mAb injection for ethical reasons showed severe inflammation in the spinal cord, whereas infiltration of the cerebellum was negligible (data not shown). This suggests that Z12 mAb cannot directly reach the cerebellum parenchyma and that the effect of Z12 mAb is indirect. IgG2a complexed to a soluble protein can enhance both B and T cell responses against that protein through interactions with activating FcgR (50) . Similarly, FcgRmediated uptake of Z12 mAb opsonized myelin breakdown products, either at the site of demyelination or after capture of antigens in the periphery (51) , could contribute to amplification of the immune response directed against myelin. Although it was beyond the scope of this study, it would be interesting to study MOG-specific T cell responses in wt and FcRg 2/2 mice at different time points after anti-MOG antibody administration.
The data presented here may be relevant for the pathology and treatment of MS. Enhanced levels of antimyelin antibodies in serum and CSF have been described MS patients (52) (53) (54) and in a subgroup of early MS patients, deposition of IgG and complement was observed in active demyelinating lesions. This suggests that antibody-mediated activation of complement plays a role in a subpopulation of MS patients (8) . In addition, intrathecal IgG production has been described as a prognostic marker for MS disease progression (55) , suggesting that antibodies may contribute to sustained CNS inflammation and demyelination in MS.
In conclusion, MOG35-55-induced EAE in FcRg
mice is delayed in onset, but otherwise indistinguishable from EAE in wt mice. This demonstrates that activating FcgR are not essential for the initiation of CNS inflammation and demyelination, although FcRg chain-mediated signal transduction may contribute to the preclinical phase of EAE. In addition, we show that anti-MOG antibodies can induce rapid exacerbation of CNS inflammation in absence of the FcgR chain, but that IgG-FcgR interactions may contribute to a sustained effect of anti-MOG antibodies on the CNS inflammatory and demyelinating response.
